JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 15, 2005; DOI: 10.1124/jpet.105.094599


0022-3565/06/3163-1175-1186$20.00
JPET 316:1175-1186, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.094599v1
316/3/1175    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, F.
Right arrow Articles by Lash, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, F.
Right arrow Articles by Lash, L. H.

TOXICOLOGY

Modulation of Expression of Rat Mitochondrial 2-Oxoglutarate Carrier in NRK-52E Cells Alters Mitochondrial Transport and Accumulation of Glutathione and Susceptibility to Chemically Induced Apoptosis

Feng Xu, David A. Putt, Larry H. Matherly, and Lawrence H. Lash

Department of Pharmacology (F.X., D.A.P., L.H.M., L.H.L.) and Experimental and Clinical Therapeutics Program, Barbara Ann Karmanos Cancer Institute (L.H.M.), Wayne State University School of Medicine, Detroit, Michigan

Received August 24, 2005; accepted November 11, 2005.


    Abstract
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
We previously showed that two anion carriers of the mitochondrial inner membrane, the dicarboxylate carrier (DIC; Slc25a10) and oxoglutarate carrier (OGC; Slc25a11), transport glutathione (GSH) from cytoplasm into mitochondrial matrix. In the previous study, NRK-52E cells, derived from normal rat kidney proximal tubules, were transfected with the wild-type cDNA for the DIC expressed in rat kidney; DIC transfectants exhibited increased mitochondrial uptake and accumulation of GSH and were markedly protected from chemically induced apoptosis. In the present study, cDNAs for both wild-type (WT) and a double-cysteine mutant of rat OGC (rOGC and rOGC-C221,224S, respectively) were expressed in Escherichia coli, purified, and reconstituted into proteoliposomes to assess their function. Although both WT rOGC and rOGC-C221,224S exhibited transport properties for GSH and 2-oxoglutarate that were similar to those found in mitochondria of rat kidney proximal tubules, rates of transport and mitochondrial accumulation of substrates were reduced by >75% in rOGC-C221,224S compared with the WT carrier. NRK-52E cells were stably transfected with the cDNA for WT-rOGC and exhibited 10- to 20-fold higher GSH transport activity than nontransfected cells and were markedly protected from apoptosis induced by tert-butyl hydroperoxide (tBH) or S-(1,2-dichlorovinyl)-L-cysteine (DCVC). In contrast, cells stably transfected with the cDNA for rOGC-C221,224S were not protected from tBH- or DCVC-induced apoptosis. These results provide further evidence that genetic manipulation of mitochondrial GSH transporter expression alters mitochondrial and cellular GSH status, resulting in markedly altered susceptibility to chemically induced apoptosis.


The mitochondrial pool of GSH in cells such as hepatocytes and renal proximal tubular cells is critical for regulation of thiol and redox status, cellular energetics, and as part of the process involved in induction of apoptosis (Beatrice et al., 1984Go; Yagi and Hatefi, 1984Go; Lê-Quôc and Lê-Quôc, 1985Go; Reed, 1990Go; Kroemer et al., 1998Go). Although free GSH is present at similar millimolar concentrations in both the mitochondrial matrix and cytoplasm, the mitochondrial GSH pool is not passively regulated. Because there is little if any de novo synthesis of GSH within the mitochondria (Griffith and Meister, 1985Go; Lash et al., 1998Go), the mitochondrial GSH pool must be derived from transport of GSH from the cytoplasm across the mitochondrial inner membrane (Smith et al., 1996Go).

Initial investigations of mitochondrial GSH transport in liver or kidney focused on the relationship between transport activity and energetics (Griffith and Meister, 1985Go; Martensson and Meister, 1989Go; Schnellmann, 1991Go). Our first approach toward understanding mitochondrial GSH transport began with the realization that GSH is an anion; hence, it may be a substrate for one or more of the various anion carriers of the mitochondrial inner membrane (McKernan et al., 1991Go). Several of the anion carriers share a common 30-kDa molecular mass subunit and are believed to belong to a carrier "superfamily" (Palmieri et al., 1996Go). Substrates for these various carriers include inorganic phosphate, citric acid cycle metabolites, and glycolytic intermediates such as lactate and pyruvate. We demonstrated an important role for two of the carriers from rat kidney mitochondria, the dicarboxylate carrier (DIC; Slc25a10) and the oxoglutarate carrier (OGC; Slc25a11), in GSH transport by assessments of substrate specificities, patterns of inhibition, and energetics in suspensions of isolated mitochondria from rat renal cortical homogenates, isolated rat proximal tubular cells, and partially purified and reconstituted carrier proteins from rabbit kidney mitochondria (McKernan et al., 1991Go; Chen and Lash, 1998Go; Lash et al., 1998Go; Chen et al., 2000Go).

Both the DIC and OGC proteins have been purified to homogeneity and reconstituted into proteoliposomes (Bisaccia et al., 1985Go, 1988Go; Kaplan and Pedersen, 1985Go; Lançar-Benba et al., 1994Go). Two difficulties with studying the purified DIC protein from mammalian tissues relate to its low abundance in the inner mitochondrial membrane and its instability in its purified form, because of autoxidation and inactivation (Kaplan and Pedersen, 1985Go; Bisaccia et al., 1988Go). To circumvent this limitation, the cDNA for the DIC from Norway rat, Rattus norvegicus, was isolated using related expressed sequence tags homologous to genes in Caenorhabditis elegans and yeast (Kakhniashvili et al., 1997Go). The rat DIC was then expressed in Escherichia coli and functionally reconstituted into proteoliposomes (Fiermonte et al., 1998Go).

In previous work (Lash et al., 2002bGo), we expressed recombinant rat DIC (rDIC) as the N-terminal polyhistidine (His6)-fusion protein from rat kidney in E. coli, reconstituted the purified DIC into proteoliposomes, and showed that it functions in transport of both dicarboxylates and GSH with properties similar to those of intact mitochondria. We then transiently transfected the cDNA for rDIC in a cell line derived from rat kidney proximal tubules (NRK-52E cells). The recombinant rDIC-His6 in transfected NRK-52E cells localizes in mitochondria whereupon it mediates GSH uptake, thereby demonstrating function of the carrier in an intact renal cell. Furthermore, overexpression of the rDIC in NRK-52E cells markedly protected against apoptosis induced by either DCVC or tert-butyl hydroperoxide (tBH), supporting the toxicological significance of the mitochondrial GSH transport process.

In the present work, we studied the function of the rOGC, as both a bacterially expressed and reconstituted protein and in transfected NRK-52E cells. We then generated a double-cysteine mutant of the rOGC and showed that it exhibits markedly lower transport activity than the wild-type (WT) carrier. cDNAs for both the wild-type and double-cysteine mutant of the rOGC were then stably transfected into NRK-52E cells to assess further the influence of genetic manipulation of mitochondrial GSH transport activity on susceptibility of the cells to chemically induced apoptosis. Our results provide further evidence that manipulation of mitochondrial GSH transport activity in a renal cell line can modulate responses to cytotoxic chemicals.


    Materials and Methods
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Experimental Design. The overall objective of this study was to determine whether modulation of mitochondrial concentrations of GSH can alter susceptibility of a renal proximal tubular cell to chemically induced apoptosis. Mitochondrial GSH status was altered by stable transfection of NRK-52E cells, a stable cell line derived from rat proximal tubules, with either the cDNA for rOGC or a double-cysteine mutant rOGC-C221,224S that exhibits markedly reduced transport function. Thus, comparisons were made between wild-type NRK-52E cells, which possess relatively low transport function and levels of mitochondrial GSH; NRK-52E cells stably overexpressing the rOGC, which possess high transport function and levels of mitochondrial GSH; and NRK-52E cells stably overexpressing the rOGC-C221,224S, which possess low-to-moderate transport function and moderate levels of mitochondrial GSH. Two well characterized mitochondrial toxicants, tBH and DCVC, were used at concentrations that are known to cause apoptosis but little or no necrosis. In addition, incubations were performed for relatively short times because this is also the time frame over which the cells primarily undergo apoptosis.

Materials. L-[3H-Glycyl]GSH (44.8 Ci/mmol) and [14C]2-OG (281 mCi/mmol) were purchased from DuPont NEN (Boston, MA). Restriction enzymes for PCR, other enzymes (e.g., DNA polymerases and T7 RNA polymerase), and plasmids were purchased from New England Biolabs (Beverly, MA), Promega (Madison, WI), and Gibco-BRL/Life Technologies (Gaithersburg, MD). PCR primers were custom synthesized by Integrated DNA Technology, Inc. (Coralville, IA). Cloning vectors (pGEM-T Easy and pRSET, pcDNA3.1/V5-His-TOPO) were purchased from Promega and Invitrogen (Carlsbad, CA). Dowex-1, Triton X-100, Percoll, phospholipids, and digitonin (aqueous type, recrystallized twice from hot ethanol) were purchased from Sigma-Aldrich (St. Louis, MO). Silicone oil (high temperature, nD = 1.4950 at 20°C, d = 1.050) and mineral oil (white, light, paraffin oil, nD = 1.4760 at 20°C, d = 0.862) were purchased from Aldrich Chemical Co. (Milwaukee, WI). Materials for gel electrophoresis (SDS, acrylamide, and agarose, buffers) were purchased from Bio-Rad (Hercules, CA) or Sigma-Aldrich. ProBond nickel-chelating resin was purchased from Invitrogen. Millicell polycarbonate filter inserts (0.2-µm pore size, 25-mm diameter) were purchased from Millipore Corporation (Billerica, MA). NRK-52E cells (catalog no. CRL-1571) and cell culture medium (catalog no. 30-2002; Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, and 1.0 mM sodium pyruvate), and 10% (w/v) bovine calf serum were purchased from the American Type Culture Collection (Manassas, VA). Antibodies to the His6-fusion proteins were purchased from Invitrogen or QIAGEN (Valencia, CA). DCVC was synthesized from trichloroethylene and L-cysteine in sodium metal and liquid ammonia (Elfarra et al., 1986Go). Purity (>95%) was assessed by high-performance liquid chromatography and thin layer chromatography, and identity was confirmed by 1H NMR. Double-distilled, deionized water was used for all experiments. All other chemicals and reagents were purchased from commercial vendors and were of the highest purity available.

Amplification of Rat Kidney Mitochondrial rOGC cDNA by RT-PCR and Bacterial Expression. Total RNA was previously isolated from renal cortical homogenates of male Fischer-344 rats (200–300 g body weight; Charles River Laboratories, Inc., Wilmington, MA) by acid phenol extraction using the TRIzol extraction kit (Gibco-BRL/Life Technologies) and was stored at –80°C until needed. Total rat kidney RNA was reverse transcribed with Super-Script II reverse transcriptase and amplified with forward and reverse primers based on the complete cDNA sequence (1149 bp) for the heart mitochondrial OGC protein from the Norway rat [sequence reported by Dolce et al. (1994Go); also see GenBank accession no. NM_022398 [GenBank] , which reports cDNA sequence corresponding to positions 42 to 987 of the above-mentioned sequence). PCR primers were designed with the aid of Oligo 6.7 (Molecular Biology Insights, Inc., Cascade, CO), based on the knowledge that the coding region is from positions 42 to 986, and were as follows: upper primer, 5'-GCC GAG GGC CAT CAA GGG ACG ATT-3', positions 21 to 43; and lower primer, 5'-ACT TGG AAA CCC TGG CAC ACG AGT CTC A-3', positions 1000 to 1027. RT-PCR was conducted by running 30 cycles of 94°C x 3 min for denaturation and 70°C x 2 min for annealing/extension. Sample was then loaded onto a 1% (w/v) agarose gel, the gel was stained with ethidium bromide, and the bands were visualized under UV light. The 1149-bp product was ligated into a T-A cloning vector (pGEM-T Easy) for transformation. Confirmation of the PCR product was by automated DNA sequencing.

The full-length cDNA for rat kidney OGC was subcloned into the pRSET T7 expression vector for high-level expression in E. coli as a His6 fusion product. Bacterial cells containing the overexpressed protein were harvested by centrifugation (5000g x 5 min at 4°C), supernatants were discarded, and pellets were resuspended in 20 ml of TE-1 buffer (50 mM Tris-HCl and 2 mM EDTA, pH 8.0). Cells were then lysed by incubation for 15 min at 30°C and occasional mixing with 100 µg of lysozyme/ml (freshly prepared in TE-1 buffer) and 0.1% (v/v) Triton X-100. Bacterial DNA in the cell lysate was sheared by sonication, the suspension was centrifuged at 12,000g x 15 min, and the pellet was resuspended in 2 ml of TE-2 buffer (10 mM Tris-HCl, 0.1 mM EDTA, and 1 mM dithioerythritol, pH 7.0) and recentrifuged. The final pellet was resuspended in 2 ml of TE-2 buffer and was solubilized with 1.2% (w/v) sarkosyl dissolved in TE-2 buffer. The inclusion body fraction was isolated by centrifugation of the resuspended pellet at 131,000g x 4.5 h through a step sucrose gradient [12.4 ml of 40% (w/v) sucrose and 18.6 ml of 53% (w/v) sucrose (sucrose solutions prepared in TE-2 buffer)]. The inclusion body pellet was resuspended in 30 ml of TE-2 buffer and centrifuged at 12,000g x 15 min. The OGC protein was then extracted by resuspension of the inclusion body pellet in 2 ml of 1.2% (w/v) Sarkosyl dissolved in TE-2 buffer and centrifugation at 314,000g x 30 min.

Purity of the rOGC-His6 fusion protein obtained from the inclusion body fraction was enhanced by fractionation of the inclusion body pellet (2 ml, approximately 25 mg of protein) on a 1.0 x 6.8-cm column with 4 ml of nickel-chelating resin and equilibrated with ProBond buffer (20 mM potassium phosphate, pH 7.8, containing 500 mM NaCl). The column was then washed with ProBond buffer adjusted to pH 6.0 (25 ml) and finally with 25 ml each of ProBond buffer, pH 6.0, containing 100 mM and then 300 mM imidazole.

Preparation of Proteoliposomes for Reconstitution of Purified rOGC. Liposomes and proteoliposomes were prepared essentially as described previously (Chen et al., 2000Go). In brief, liposomes were prepared by transferring 700 mg of phosphatidylcholine into a 30-ml polypropylene tube and drying under a stream of nitrogen. After redissolving the dried lipid in diethyl ether and removal of solvent under nitrogen, liposome buffer (7 ml; 120 mM HEPES, 50 mM KCl, and 1 mM EDTA, pH 7.0) was added to the dried lipid, and the tube was flushed with nitrogen, sealed, and vigorously mixed on a vortex mixer. Lipid was then dispersed in a bath sonicator for approximately 60 min and was stored at –80°C for up to 3 months. Proteoliposomes were prepared by mixing purified carrier protein (200 µl; 50 µg of protein) or liposome buffer (for a blank control) with 0.5 ml of liposomes and 50 µl of substrate solution (buffer containing 20 mM 2-OG) in a final volume of 1 ml. After mixing on a vortex mixer, the proteoliposomes were rapidly frozen in liquid nitrogen and stored at –80°C for up to 1 month until use. Immediately before assay, the proteoliposome suspension was thawed, sonicated with a bath sonicator at room temperature, placed on ice for 1 min, and then passed through an anion exchange column (Dowex-1, 100–200 mesh; equilibrated with liposome buffer and prepared in a 9-inch Pasteur pipette) to remove external substrate by elution with liposome buffer. The opalescent fraction (approximately 1 ml) containing the proteoliposomes was collected. The proteoliposomes were equilibrated at room temperature for approximately 5 min before being used in transport assays. This freeze-thaw cycle and sonication method gives rise to a heterogeneous population of large, primarily unilamellar proteoliposomes that are suitable for transport studies (Kaplan and Pedersen, 1985Go).

Transport Assays in Reconstituted Proteoliposomes. Transport of substrates (i.e., GSH and 2-OG) into proteoliposomes was measured by first preincubating 200 µl of proteoliposomes (preloaded with 1 mM 2-OG) for 1 min with 12 µl of "reconstitution buffer" (120 mM HEPES, 50 mM KCl, and 1 mM EDTA, pH 7.4). Competitive inhibitors were added simultaneously with substrates. Transport was initiated by addition of 12 µl of 20x radiolabeled substrate. At various times (30–240 s), 30-µl aliquots were transferred to a microcentrifuge tube containing 70 µl of reconstitution buffer + 40 mM of an irreversible transport inhibitor (i.e., PLP), and tubes were mixed and placed on ice until the next processing step. After completion of time courses, samples were loaded onto Sephacryl S-100 mini-columns, which were prepared in 5.75-inch Pasteur pipettes. These columns were placed in 16 x 125-mm glass test tubes and were centrifuged at 2300 rpm x 2 min in a tabletop clinical centrifuge. Supernatant from each tube was transferred to a 5-ml scintillation vial, and each tube was washed with 200 µl of scintillation fluid, which was then added to scintillation vials.

Uptake rates were calculated by linear curve-fitting as described previously (Chen and Lash, 1998Go; Chen et al., 2000Go), plotting ln[Ptotal/(Ptotal – Pt)] versus time according to Halestrap (1975Go). Ptotal represents the total uptake of substrate at equilibrium (estimated by exponential decay curve fitting of time-course data), and Pt represents substrate uptake at time t (0–5 min). The initial rates of uptake were then determined from the first-order rate equation v = k (Ptotal).

As a control, liposomes were reconstituted with either buffer and no protein or protein that was inactivated by boiling for 5 min. These control liposomes exhibited less than 5% of the measured uptake of either GSH or 2-OG (data not shown), similar to previous reconstitution studies (Chen et al., 2000Go), indicating that nearly all of the measured substrate transport was because of the function of the reconstituted carrier protein.

Site-Directed Mutagenesis for Generation of a Double-Cysteine Mutant of rOGC. A double-cysteine mutant of the rOGC (rOGC-C221,224S), in which C221 and C224 were converted to S, was generated by nested PCR using two sets of upstream and downstream primers: upstream primer 1, 5'-GCC GAG GGC CAT CAA GGG ACG AT-3' and downstream primer 1, 5'-GCG GAG AAG TGG GAC AGA ATG TTG TCA G-3'; and upstream primer 2, 5'-ATT CTG TCC CAC TTC TCC GCC AGC ATG AT-3' and downstream primer 2, 5'-GAC TTG GAA ACC CTG GCA CAC GAG TCT CA-3'. The double-cysteine mutant rOGC-C221,224S was expressed in E. coli as the N-His6 fusion protein, purified from inclusion bodies and by Ni2+-affinity chromatography, and reconstituted into proteoliposomes as described above for the wild-type rOGC.

Culture of NRK-52E Cells. NRK-52E cells were cultured on collagen-coated, polystyrene T-25 or T-175 culture flasks with Dulbecco's modified Eagle's medium containing 4% (w/v) glutamine, 1.5 g/l sodium bicarbonate, 4.5 g glucose/l, 1 mM sodium pyruvate, and 10% (v/v) bovine calf serum in an atmosphere of 5% CO2, 95% air at 37°C. On reaching confluence (5–9 days), subcultures were prepared by a 15-min treatment with 0.02% (w/v) EDTA, 0.05% (w/v) trypsin solution, and replating the cells at a density of 4 x 104 cells/cm2.

Transfection of NRK-52E Cells. Plasmid DNA was purified, following amplification in E. coli cells, using the Promega Wizard Prep purification kit. cDNAs for either wild-type rOGC or rOGC-C221,224S were subcloned into the pcDNA3.1/V5-His-TOPO vector and stably transfected into the NRK-52E cells with FuGENE 6 from Roche Applied Science (Indianapolis, IN). Transfections were carried out as described by the manufacturer using a 3:1 ratio of FuGENE 6 reagent to plasmid DNA. After 24 h, cells were harvested by incubating with Cellstripper (Mediatech, Herndon, VA) for 5 min and gentle scraping. Stable transfectants were selected with Geneticin (G418).

Isolation of Mitochondria from NRK-52E Cells and Transport Measurements. Mitochondria were prepared from seven confluent T-175 flasks, which contained approximately 70 to 85 x 106 NRK-52E cells, by differential centrifugation as described previously (McKernan et al., 1991Go). Yields of mitochondrial protein ranged from 6 to 10.5 mg. Purity of mitochondria was determined by measurement of activities of marker enzymes for mitochondria (succinate dehydrogenase and glutamate dehydrogenase), plasma membrane [alkaline phosphatase, (Na++K+)-stimulated ATPase], cytoplasm (lactate dehydrogenase), and endoplasmic reticulum (glucose 6-phosphatase) in whole cells and the mitochondrial fraction (Lash et al., 2002aGo). Most of the total cellular activity of the mitochondrial marker enzymes (≥75%) was recovered in the mitochondrial fraction, whereas minimal-to-modest amounts of total cellular activity of markers for the other subcellular organelles were recovered in this fraction. Specifically, approximately 5% of total cellular activity of markers for the plasma membrane and endoplasmic reticulum and <2% of total activity of the cytoplasmic marker enzyme were recovered in the mitochondrial fraction. This indicates that the mitochondrial fraction obtained from the NRK-52E cells is of high purity and has minimal contamination with other subcellular organelles.

For transport measurements, mitochondria were suspended in 3 ml of sucrose-triethanolamine buffer in 25-ml Erlenmeyer flasks. Radiolabeled 2-OG (1 mM final concentration, containing 0.8 µCi; 147 cpm/nmol) or GSH (5 mM final concentration, containing 0.8 µCi; 23.4 cpm/nmol) was added to initiate transport. Aliquots (0.5 ml) were removed at 1, 2, 5, and 10 min and were added to 1.5-ml microcentrifuge tubes, which were centrifuged at 13,000g x 30 s. The mitochondrial pellets were washed twice with buffer, suspended in 0.5 ml of buffer, and transferred to a scintillation vial, and radioactivity was determined. No differences were observed if measurements were performed in mitochondria treated with antimycin A to inhibit metabolism, as found previously (Chen and Lash, 1998Go).

SDS-Polyacrylamide Gel Electrophoresis and Western Blotting. For gel electrophoresis, 10 or 20 µg of protein was loaded per well onto a 10% (w/v) or a 12% (w/v) polyacrylamide gel (Bio-Rad), and separation was achieved according to the method of Laemmli (1970Go). Total protein was visualized by staining with Coomassie Brilliant Blue G. For Western blot analysis, protein was transferred by electroblotting to a nitrocellulose membrane (MSI, Westborough, MA), blocked with 3% (w/v) bovine serum albumin (Promega), washed with Tris-buffered saline containing Tween 20, probed with a monoclonal anti-RGSHHHH tag antibody (QIAGEN), washed with Tris-buffered saline containing Tween 20, and then probed with an anti-mouse IgG antibody conjugated to alkaline phosphatase (Jackson ImmunoResearch Laboratories Inc., West Grove, PA). Immunoreactive bands were visualized following incubation with a solution containing 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium (Promega).

Digitonin Fractionation of NRK-52E Cells and Analysis of Mitochondrial Contents of Substrates. To analyze distribution of transported substrates into mitochondria of NRK-52E cells, subcellular fractions were separated by digitonin fractionation (Lash et al., 1998Go). In brief, microcentrifuge tubes (1.5-ml capacity) were layered from the bottom with 0.25 ml of 40% (v/v) glycerol, 0.5 ml of silicone oil/paraffin oil (6:1), and 0.1 ml of Mes buffer (19.8 mM Mes, pH 7.4, containing 19.8 mM EGTA, 19.8 mM EDTA, and 0.25 M mannitol) ± 0.15 mg of digitonin. To fractionate cells, 0.5-ml aliquots of cells were mixed with the top layer, and microcentrifuge tubes were centrifuged at 13,000g x 3 min. In the absence of digitonin, the supernatant = extracellular medium and the pellet = total cellular contents. In the presence of digitonin, the supernatant = extracellular medium + cytoplasm and the pellet = mitochondrial fraction.

Flow Cytometry Analysis of Cell Cycle and Quantitation of Apoptosis. Cell cultures were washed twice with sample buffer (phosphate-buffered saline plus 1 g glucose/l filtered through a 0.22-µm filter), dislodged by trypsin/EDTA incubation, centrifuged at 400g x 10 min at 22°C, and resuspended in sample buffer. Cell concentrations were adjusted to 1 to 3 x 106 cells/ml with sample buffer, and 1 ml of the cell suspension was centrifuged at 400g x 10 min at 22°C. All of the supernatant except 0.1 ml/106 cells was removed, and the remaining cells were mixed on a vortex mixer in the remaining fluid for 10 s. Next, 1 ml of ice-cold ethanol [70% (v/v)] was added to the sample in a dropwise manner, with samples being mixed for 10 s between drops. Tubes were capped and fixed in ethanol at 4°C. After fixation, cells were stained with propidium iodide (50 µg/ml) containing RNase A (100 U/ml). Samples were then mixed, centrifuged at 1000g x 5 min at 22°C, and all the ethanol except 0.1 ml was removed. Cells were mixed in the residual ethanol, and 1 ml of the propidium iodide staining solution was added to each tube. After mixing again, cells were incubated at room temperature for at least 30 min. Samples were analyzed within 24 h by flow cytometry using a Becton Dickinson FACSCalibur flow cytometer, which is a core facility of the National Institute of Environmental Health Sciences Center for Molecular Toxicology with Human Applications at Wayne State University (Detroit, MI). Analyses were performed with 20,000 events per sample using the ModFit LT version 2 for Macintosh data acquisition software package (Verity Software House, Topsham, ME; distributed by Becton Dickinson Immunocytochemistry System, San Jose, CA). Propidium iodide was detected by the FL-2 photomultiplier tube. Fractions of apoptotic cells were quantified by analysis of the sub-G1 (subdiploid) peak with ModFit cell cycle analysis. The percentage of distribution of cells in the various stages of the cell cycle (G0/G1, S, and G2/M) was also calculated. Cell aggregates were discarded in the flow cytometry analysis by postfixation aggregate discrimination.

Data Analysis. Data were normalized to protein content, which was determined by the bicinchoninic acid protein assay from Pierce Chemical (Rockford, IL). All measurements were performed three to five times. Significant differences between means were first assessed by a one-way or two-way analysis of variance, depending on the comparisons being tested. When significant "F values" were obtained, the Fisher's protected least significant difference t test was performed to determine which means were significantly different from one another, using a two-tail probability, P < 0.05, as the criteria for significance.


    Results
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Tissue-Specific Variations in rOGC cDNA and Amino Acid Sequences. In the course of amplifying the cDNA of mitochondrial OGC using total rat kidney RNA as a template, we discovered that the sequence of our PCR products exhibited significant differences from the rat heart and brain mitochondrial OGC cDNAs, which are the only two rat tissues from which the mitochondrial OGC cDNA sequence is available in either the literature or in GenBank (Table 1). The PCR reaction was performed on 10 separate occasions, each time with the identical sequence being obtained for the product. Nucleotide differences were observed for 6 bp between kidney and heart and for 10 bp between kidney and brain. Amino acid differences for deduced sequences include two residues between kidney and heart and six residues between kidney and brain. Although neither of the two amino acid differences between kidney and heart OGC is in predicted transmembrane domains (TMDs) and both are substitutions of amino acids that are similar in terms of charge and polarity (T for A and T for I), two of the amino acid differences between kidney and brain OGC are in predicted TMDs (TMD2 and TMD3), and one difference is very close to TMD1. Two of these differences are substitutions of amino acids that differ by charge or polarity (K for N and T for P) and therefore could have a significant effect on protein tertiary structure.


View this table:
[in this window]
[in a new window]
 
TABLE 1 Tissue-specific differences in nucleotide and amino acid sequences of rat OGC

The published nucleotide and amino acid sequences from the heart, brain, and liver of the rat noted are compared with those of the rat kidney that we obtained in our current study. Sequences were aligned using BLAST.

 

There is also uncertainty about the identity of transporters for 2-OG and GSH in rat liver. Although rat liver OGC may have a high degree of homology with rat brain OGC (Coll et al., 2003Go), its sequence has not been reported. Although many of the reported properties of GSH and 2-OG transport in rat liver mitochondria are similar to what we have found in rat kidney mitochondria (Coll et al., 2003Go), GSH transport in rat liver mitochondria was inhibited by L-glutamate, which differs from our previous findings. A thorough search of the GenBank database and the published literature, however, failed to find any cDNA or amino acid sequences for the OGC from rat liver mitochondria. Fiermonte et al. (2001Go), however, reported cloning and expression of a rat liver oxodicarboxylate carrier that transports 2-OG and other C5-C7 dicarboxylates. They isolated a 1456-bp cDNA with a 99-bp 5'-untranslated region, an open reading frame of 897 bp, and a 460-bp 3'-untranslated region. The cDNA encodes a polypeptide of 298 amino acids with a molecular mass of 33,276 kDa, which contrasts with the OGC from rat kidney, heart, and brain mitochondria, which are all 314 amino acids.

Bacterial Expression of the rOGC and rOGC-C221,224S. The OGC contains three cysteinyl residues (C184, C221, and C224), with the latter two being linked in a disulfide bond in the native protein (Palmieri et al., 1996Go).

Considering that the two latter cysteinyl residues are conserved across species (for the limited number of species for which the cDNA and deduced amino acid sequences are published), that they are in TMD3, and that alteration of disulfide bridges should alter protein structure and function, we mutated both cysteinyl residues to serines and investigated effects on transport function and the ability of NRK-52E cells transfected with the cDNA for the double-cysteine mutant to be protected from toxicant-induced apoptosis.


Figure 1
View larger version (53K):
[in this window]
[in a new window]
 
Fig. 1. Coomassie-stained SDS gels (A and B) and immunoblots (C and D) of wild-type (A and C) and double-cysteine mutant (B and D) rOGC expressed in E. coli. Positive clones from BL21 Lys S cells were transformed with the pRSET B-OGC-WT (A and C) or pRSET C-OGC-C221,224S (B and D) cDNA inserts and were grown for 2 h (A and B) or for 0, 1, or 2 h (C and D) in the presence of isopropyl beta-D-thiogalactoside. Cells were then solubilized and put through several freeze-thaw cycles. Lysed cells were centrifuged at 10,000g x 5 min, and 20-µg protein was electrophoresed on 12% (w/v) polyacrylamide gels in the presence of SDS. A, lane 1, flow-through from Ni2+-affinity column; lane 2, standards; lanes 3 and 4, column wash; and lanes 5–7, column elution fractions. B, lane 1, E. coli extract; lane 2, standards; lane 3, flow-through from Ni2+-affinity column; lanes 4 and 5, column wash; and lanes 6–8, column elution fractions. Arrow, rOGC band. C and D, the presence of either the OGC-WT-His6 or OGC-C221,224S-His6 fusion proteins in inclusion bodies were confirmed by Western blots using a monoclonal anti-RGSHHHH tag antibody with chemiluminescence detection. Expected products of 34 to 37 kDa were obtained.

 
The full-length cDNAs for WT rOGC and the double-cysteine mutant rOGC-C221,224S were expressed in E. coli as N-His6 fusion proteins and purified from inclusion bodies followed by Ni2+-affinity chromatography. Analysis by Coomassie staining of SDS gels for presence of rOGC-His6 (Fig. 1A) or rOGC-C221,224S-His6 (Fig. 1B) showed that a substantial degree of purification was achieved by passing the solubilized material from the inclusion body fraction through the Ni2+-affinity column (Fig. 1A, compare lane 1 with lanes 5–7, and Fig. 1B, compare lane 1 with lanes 6–9). Isopropyl beta-D-thiogalactoside-stimulated, time-dependent increases in protein expression, as shown by Western blot analysis using the monoclonal anti-RGSHHHH tag antibody, with the expected molecular mass of 34 to 37 kDa, were observed for both the WT (Fig. 1C) and double-cysteine mutant (Fig. 1D) carriers. The overall yield of both the WT and double-cysteine mutant proteins from a 1-liter culture of bacteria was typically 20 to 25 mg of protein.

Reconstitution and Transport Function of rOGC and rOGC-C221,224S. The bacterially expressed and purified rOGC was reconstituted in proteoliposomes for assessment of its ability to transport 2-OG and GSH. Similar to results with the partially purified and reconstituted inner membrane transporter preparation (Chen et al., 2000Go), the expressed and reconstituted rOGC exhibited time- and concentration-dependent up-take of both 2-OG (Fig. 2A) and GSH (Fig. 2B) with maximal accumulation of substrate after 2 to 3 min of incubation, followed by a decrease at later time points. This spike is consistent with heteroexchange of trans- for cis-substrate. As two controls, liposomes were either reconstituted without added purified protein and uptake of substrates was measured or protein was boiled before incorporation into proteoliposomes and measurement of uptake. As found in our previous studies (Chen et al., 2000Go; Lash et al., 2002bGo), both controls exhibited <5% of the apparent uptake of radiolabeled 2-OG or GSH, indicating that transport in the proteoliposomes is because of a catalytically active protein (data not shown).


Figure 2
View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2. Time and concentration dependence of 2-OG (A) and GSH (B) uptake by amplified, bacterially expressed, and reconstituted rOGC-His6. Uptake of [14C]2-OG or [3H]GSH was measured in proteoliposomes preloaded with 1 mM malate. At the indicated times, aliquots of incubation mixtures were mixed with 40 mM PLP and centrifuged through Sephacryl S-100 minicolumns. Eluates were placed in scintillation vials for determination of radioactivity. Results are means ± S.E.M. of measurements from four separate preparations.

 
Initial rates of uptake were derived as described under Materials and Methods, and Eadie-Hofstee plots were constructed to derive kinetic parameters (Table 2). The results show that 2-OG is a much better substrate for the rOGC than is GSH, with the carrier having a 6.9-fold lower Km value for 2-OG than for GSH, although the Km value for GSH is well within the range of normal concentrations of GSH in proximal tubular cytoplasm. Vmax values for 2-OG or GSH as substrates were similar.


View this table:
[in this window]
[in a new window]
 
TABLE 2 Comparison of kinetic parameters for transport of 2-OG and GSH by bacterially expressed, purified, and reconstituted OGC-WT and OGC-C221,224S

Uptake rates of 2-OG and GSH for the WT and double-cysteine mutant carriers were derived from Eadie-Hofstee plots of 1-min uptake rates derived from data shown in Figs. 2 and 3.

 


Figure 3
View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3. Time and concentration dependence of 2-OG (A) and GSH (B) uptake by amplified, bacterially expressed, and reconstituted rOGC-C221,224S-His6. Uptake of [14C]2-OG or [3H]GSH was measured in proteoliposomes preloaded with 1 mM malate. At the indicated times, aliquots of incubation mixtures were mixed with 40 mM PLP and centrifuged through Sephacryl S-100 minicolumns. Eluates were placed in scintillation vials for determination of radioactivity. Results are means ± S.E.M. of measurements from four separate preparations.

 
Bacterially expressed, purified, and reconstituted rOGC-C221,224S likewise exhibited time- and concentration-dependent uptake of both 2-OG (Fig. 3A) and GSH (Fig. 3B). Similar to transport function for the rOGC-WT, intravesicular accumulation of either substrate exhibited maximal values at approximately 2 min, with modest decreases thereafter. Analysis of kinetic parameters for each substrate by Eadie-Hofstee plots using calculated initial rates (Table 2) showed that the double-cysteine mutant carrier exhibited a 70 and 81% decrease in Vmax for 2-OG and GSH, respectively, and a 13.6-fold and 14.4% increase in Km for 2-OG and GSH, respectively. In spite of the modest effect on the Km value for GSH, it is clear that the transport function of the double-cysteine mutant is markedly diminished compared with that of the wild-type carrier. Transport activity of both the rOGC-WT and rOGC-C221,224S with either 2-OG or GSH as substrate was markedly (>80%) inhibited by either PLP or phenylsuccinate (PhSucc) (Figs. 4 and 5), which is consistent with the expected sensitivity of the carrier.


Figure 4
View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4. Inhibition of 2-OG (A) and GSH (B) uptake in amplified, expressed, and reconstituted rOGC-His6 by PLP and PhSucc. Uptake of 1 mM [14C]2-OG or [3H]GSH was measured in proteoliposomes preloaded with 1 mM malate and in the presence of either substrate alone or with 40 mM PLP or 10 mM PhSucc. Samples were processed for determination of radioactivity as described in the legend to Figs. 2 and 3, and results are means ± S.E.M. of measurements from four separate preparations.

 

Figure 5
View larger version (16K):
[in this window]
[in a new window]
 
Fig. 5. Inhibition of 2-OG (A) and GSH (B) uptake in amplified, expressed, and reconstituted rOGC-C221,224S-His6 by PLP and PhSucc. Uptake of 1 mM [14C]2-OG or [3H]GSH was measured in proteoliposomes preloaded with 1 mM malate and in the presence of either substrate alone or with 40 mM PLP or 10 mM PhSucc. Samples were processed for determination of radioactivity as described in the legend to Figs. 2 and 3, and results are means ± S.E.M. of measurements from four separate preparations.

 

Effect of Stable Transfection of NRK-52E Cells with cDNAs for rOGC-WT and rOGC-C221,224S on Susceptibility to Chemically Induced Apoptosis. NRK-52E cells were stably transfected with either the cDNA for rOGC-WT or rOGC-C221,224S by selection with G418. Expression of the rOGC-WT protein (Fig. 6A) and the rOGC-C221,224S protein (Fig. 6B) in mitochondrial extracts from stably transfected NRK-52E cells was confirmed by Western blot analyses using the monoclonal anti-RGSHHHH tag antibody.


Figure 6
View larger version (26K):
[in this window]
[in a new window]
 
Fig. 6. Immunoblots of wild-type OGC (A) and OGC-C221,224S (B) from rat kidney mitochondria in NRK-52E cells. Mitochondria from three stable transfectants of NRK-52E cells expressing the wild-type OGC (A) or from two stable transfectants expressing the OGC-C221,224S mutant (B) were solubilized and put through several freeze-thaw cycles. Lysed mitochondria were centrifuged at 10,000g x 5 min, and 20 µg of protein was electrophoresed on a 12% (w/v) polyacrylamide gel in the presence of SDS. Presence of the OGC-His6 or OGC-C221,224S-His6 fusion proteins was confirmed by Western blots using the anti-His-C-terminal antibody with chemiluminescence detection. The expected product of 34 to 37 kDa was obtained.

 
Before determining the influence of expression of either wild-type or mutant rOGC in the NRK-52E cells on susceptibility to chemically induced apoptosis, we compared the ability of mitochondria from the three cell populations (i.e., nontransfected cells, NRK-52E-WT; cells transfected to overexpress rOGC, NRK-52E-rOGC; and cells transfected to overexpress the double-cysteine mutant carrier, NRK-52E-rOGC-C221,224S) to accumulate either GSH (Fig. 7) or 2-OG (Fig. 8). Each population of NRK-52E cells was incubated with the indicated concentrations of either substrate for various times up to 60 min, and cell samples were washed and fractionated by digitonin treatment to separate cytoplasmic and mitochondrial compartments. Results shown for 30-min incubations indicate that cells overexpressing rOGC exhibited markedly higher contents of GSH in mitochondria than either NRK-52E-WT or NRK-52E-rOGC-C221,224S cells, with the latter cell population exhibiting the lowest content of GSH in mitochondria (Fig. 7A). The increase in contents of mitochondrial GSH were prevented by including the rOGC inhibitor PhSucc (Fig. 7B), demonstrating that the alterations in mitochondrial contents of GSH were because of rOGC. Concentrations of GSH in the cytoplasm of the three populations of NRK-52E cells incubated with exogenous GSH were also measured (data not shown). Although differences between the three cell populations were observed, these differences were smaller than those for mitochondrial GSH contents and exhibited an inverse pattern among the three cell populations compared with the pattern for mitochondria. Thus, the highest GSH concentrations in cytoplasm were observed in NRK-52E-WT cells, whereas the lowest GSH concentrations in cytoplasm were observed in NRK-52E-rOGC cells. The NRK-52E cells overexpressing the double-cysteine mutant exhibited intermediate levels of GSH in the cytoplasm.


Figure 7
View larger version (15K):
[in this window]
[in a new window]
 
Fig. 7. GSH content in mitochondria of populations of NRK-52E cells transfected with either nothing (WT) or the cDNA for rOGC or rOGC-C221,224S. Each of the populations of NRK-52E cells was grown to confluence on T-25 flasks and incubated with 1, 5, or 10 mM GSH containing 0.1 µCi of L-[3H-glycyl]GSH in the absence (A) or presence (B) of 10 mM PhSucc for 15, 30, or 60 min. Cells were removed from flasks and fractionated by digitonin treatment to quantify content of GSH in the mitochondrial fraction. Results are shown for 30-min incubations and are means ± S.E.M. of measurements from three to four cell cultures. *, significantly different (P < 0.05) from the corresponding sample from WT cells.

 

Figure 8
View larger version (16K):
[in this window]
[in a new window]
 
Fig. 8. 2-OG content in mitochondria of populations of NRK-52E cells transfected with either nothing (WT) or the cDNA for rOGC or rOGC-C221,224S. Each of the populations of NRK-52E cells were grown to confluence on T-25 flasks and incubated with 0.2, 0.5, or 1 mM 2-OG containing 0.1 µCi of [14C]2-OG in the absence (A) or presence (B) of 10 mM PhSucc for 15, 30, or 60 min. Cells were removed from flasks and fractionated by digitonin treatment to quantify content of 2-OG in the mitochondrial fraction. Results are shown for 30-min incubations and are means ± S.E.M. of measurements from three to four cell cultures. *, significantly different (P < 0.05) from the corresponding sample from WT cells.

 

Similar incubations using 2-OG as transporter substrate also demonstrated markedly increased mitochondrial contents of 2-OG in NRK-52E-rOGC cells compared with either nontransfectants or cells expressing the double-cysteine mutant (Fig. 8A). Coincubation with 10 mM PhSucc also markedly diminished most of the increased contents of mitochondrial 2-OG (Fig. 8B), indicating that the altered mitochondrial contents of 2-OG were largely because of the different levels of activity of the OGC.

The three populations of NRK-52E cells were then incubated for 1, 2, or 4 h with either media (=control), 10 or 50 µM tBH, or 50 or 200 µM DCVC for assessment of the fraction of cells undergoing apoptosis (Fig. 9). Although all three populations of control cells exhibited <1.5% apoptosis throughout the 4-h time course, NRK-52E-WT cells exhibited dose-dependent increases in the fraction of cells undergoing apoptosis after exposure to either tBH or DCVC at all time points, with increases after 1- to 2-h incubations and slightly less apoptosis after 4-h incubations (Fig. 9, A–C). This decrease by the 4-h time point is probably because of cells losing competence to undergo apoptosis and switching to necrosis as a mode of cell death (also see Lash et al., 2002aGo,bGo). NRK-52E-rOGC cells, in contrast, exhibited very small increases in apoptosis after toxicant exposures, indicating significant protection (Fig. 9, D–F). NRK-52E-rOGC-C221,224S cells, however, exhibited comparable amounts of apoptosis as NRK-52E-WT cells. Maximal amounts of apoptotic cells (12–13%) were observed with NRK-52E-rOGC-C221,224S cells incubated for 2 h with either 50 µM tBH or 200 µM DCVC (Fig. 9, G–I).


Figure 9
View larger version (38K):
[in this window]
[in a new window]
 
Fig. 9. Influence of modulation of mitochondrial GSH transport activity on susceptibility of NRK-52E cells to tBH- and DCVC-induced apoptosis. NRK-52E cells [either wild-type (WT; A–C) or those stably transfected to overexpress either the normal cDNA for rOGC (rOGC; D–F) or the double-mutant containing two cysteine residues converted to serines by RT-PCR (rOGC-C221,224S; G–I) were preincubated for 24 h with 1 mM GSH and then incubated for up to 4 h with either medium (=control), tBH (10 or 50 µM), or DCVC (50 or 200 µM). The fraction of cells undergoing apoptosis was estimated by propidium iodide staining and flow cytometry. Results are means ± S.E.M. of five separate experiments for WT cells and four separate experiments for each of the transfectants. *, significantly different (P < 0.05) from the corresponding control sample. {dagger}, significantly different (P < 0.05) from WT cells incubated under the same conditions.

 


    Discussion
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
The present study sought to further define the role of mitochondrial GSH transporters in determining the susceptibility of renal proximal tubular cells to chemically induced apoptosis, focusing on the OGC and using NRK-52E cells as a model system. NRK-52E cells are an excellent model in which to examine these processes because they exhibit many properties of in vivo proximal tubules, including retention of epithelial morphology and expression of high activities of the (Na++K+)-ATPase and several enzymes of the GSH redox cycle (Lash et al., 2002aGo). Unlike the in vivo proximal tubule and similar to other epithelial-derived, immortalized cell lines, NRK-52E cells exhibit relatively low activities of brush-border membrane enzymes and relatively low activities of mitochondrial respiration, transport, and dehydrogenase enzymes (Lash et al., 2002aGo). Whereas mitochondrial GSH content represents approximately 30% of the total cellular pool of GSH in the in vivo rat proximal tubule (Schnellmann et al., 1988Go; Lash et al., 1998Go), it comprises only 8 to 10% of the total cellular GSH pool in NRK-52E cells. In spite of this, the relatively high activity of the (Na++K+)-ATPase argues that cellular supplies of ATP, and hence mitochondrial function, are adequate for cellular work under normal, physiological conditions. These differences between NRK-52E cells and the in vivo proximal tubule actually facilitate our transport measurements because they provide a model that has low activity of GSH degradation and a low baseline level of mitochondrial transport activity. Although it can be argued that the NRK-52E cells are inherently more sensitive than the in vivo rat proximal tubule to toxicants because of their lower mitochondrial GSH content, the ability to modulate mitochondrial GSH contents over a wide range of values, which include those that greatly exceed those in the in vivo proximal tubule, allows us to directly test the hypotheses we have posed.

After amplification of the cDNA for the rOGC using total rat kidney cortex RNA as a template, comparison of the kidney rOGC DNA sequence with those of the rOGC from rat heart and brain showed differences between these published sequences and that for our PCR product from rat kidney. Moreover, comparison of the deduced amino acid sequences from the rat kidney PCR product with that from rat heart and brain showed two- and six-amino acid residue differences, respectively, two of which between our rat kidney product and that from rat brain differed by polarity or charge. Because these two differences are in TMDs and probably lead to changes in protein three-dimensional structure, catalytic function of the rOGC from rat kidney and brain may differ. This suggests that tissue-specific differences may exist in the rOGC.

Although the cDNA sequence for rat liver OGC is not published in GenBank, Coll et al. (2003Go) used the cDNA sequence from rat brain OGC to design primers to detect expression of the OGC in rat liver. From this, one would conclude that the cDNA sequence for rat liver OGC is very similar to or the same as that from rat brain. To complicate matters, however, Fiermonte et al. (2001Go) identified a carrier, called the oxodicarboxylate carrier, that transports 2-OG but exhibits no significant cDNA sequence homology and only 25 to 27% amino acid homology with the deduced amino acid sequences of our cDNA clone or the two published sequences of rOGC from heart or brain. Repetition of the PCR reaction 10 times, with confirmation by sequencing the PCR cDNA product and expression, purification, and functional reconstitution of the OGC protein, provides confidence that the sequence differences among tissues are real and not because of PCR artifacts. Although additional work is required to clarify the identity and function of carriers for 2-OG and GSH in rat liver, the possibility that the cDNA and deduced amino acid sequences of our OGC cDNA from rat kidney differ significantly from those of other tissues warrants further study.

Transport properties of the amplified, bacterially expressed, and reconstituted rOGC from kidney were consistent with the function of this carrier that we observed previously in suspensions of rat kidney mitochondria (Chen and Lash, 1998Go) and in proteoliposomes reconstituted with a partially purified preparation of mitochondrial inner membrane carriers from rabbit kidney mitoplasts (Chen et al., 2000Go). These similarities included a lower Km but a higher Vmax value for 2-OG than for GSH as transport substrate and inhibition of transport by PLP and PhSucc.

In a previous study (Lash et al., 2002bGo), we demonstrated that transient overexpression of the cDNA for the rDIC in NRK-52E cells produced a 3- to 11-fold increase in mitochondrial GSH content and protected the cells from tBH- and DCVC-induced apoptosis. Because our previous work (Chen and Lash, 1998Go) concluded that the rDIC and rOGC contributed approximately 60 and 40%, respectively, to the uptake of GSH from cytoplasm into mitochondrial matrix, our expectation was that overexpression of the rOGC in NRK-52E cells would also provide significant protection from tBH- and DCVC-induced apoptosis. Indeed, this expectation was realized because stably transfected NRK-52E cells that overexpressed the rOGC were almost completely protected and significantly protected, respectively, from tBH- and DCVC-induced apoptosis. The difference in the ability to protect from tBH- and DCVC-induced apoptosis probably lies in the distinct mechanisms of action of the two toxicants. Whereas tBH can be described as a "pure" oxidant that causes lipid peroxidation and GSH oxidation in mitochondria (McKernan et al., 1991Go), DCVC exerts mitochondrial toxicity by at least two mechanisms, including both an oxidative stress with increased lipid peroxidation and GSH oxidation (Lash and Anders, 1987Go), and inhibition of mitochondrial dehydrogenases by alkylation (Lash and Anders, 1987Go; Hayden and Stevens, 1990Go; van de Water et al., 1995Go; Cooper et al., 2002Go). The NRK-52E-rOGC cells also exhibited markedly higher contents of mitochondrial GSH than NRK-52E-WT cells when each population was incubated with exogenous GSH (cf. Fig. 7), indicating that the protection was associated with an enhanced ability of the transfectants to accumulate GSH in their mitochondria.

Although most previous studies of tBH- and DCVC-induced cellular injury have focused on the association of their biochemical effects with cellular necrosis, this occurs at much higher doses of toxicants than were used in the present study. Thus, although both tBH and DCVC can cause oxidation of mitochondrial GSH and cellular necrosis (Lash and Anders, 1987Go; McKernan et al., 1991Go; Lash et al., 1998Go), these same toxicants can result in apoptosis under appropriate exposure conditions (Lash et al., 2001Go). The pronounced oxidation of the mitochondrial GSH pool and lipid peroxidation described previously occurred at much higher concentrations than those used in the present study.

To explore how much mitochondrial GSH is necessary and sufficient to protect NRK-52E cells, we constructed a double-cysteine mutant of the renal rOGC by site-directed mutagenesis. Although amplified, bacterially expressed, and reconstituted rOGC-C221,224S exhibited similar sensitivity to PLP and PhSucc as the wild-type carrier, it exhibited markedly lower catalytic efficiency (i.e., Vmax/Km values) for transport of 2-OG and GSH. NRK-52E-rOGC-C221,224S cells were no less sensitive than NRK-52E-WT cells to tBH- and DCVC-induced apoptosis. This lack of protection suggests that there is a threshold in the mitochondrial content of GSH that is needed to prevent cell death from oxidants or other mitochondrial toxicants. Consistent with this conclusion, mitochondrial accumulation of GSH was modestly lower in NRK-52E-rOGC-C221,224S cells than in NRK-52E-WT cells (cf. Fig. 7). This conclusion is also consistent with observations that certain forms of chemically induced cytotoxicity, notably oxidative stress, are dependent on depletion of mitochondrial GSH below a certain level (Martensson and Meister, 1989Go; Reed, 1990Go; Shan et al., 1993Go; Fernandez-Checa et al., 1997Go). Comparison of the extent of protection by overexpression of the rOGC over time, which was greater in the 1- and 2-h incubations than in the 4-h incubation, suggests that enhancing mitochondrial GSH content delays the progress of cellular injury.

In summary, the present study has provided additional evidence that manipulation of mitochondrial GSH transport function can modulate renal cellular susceptibility to toxicants and has provided insight into the limitations of GSH levels required to elicit protection, consistent with the existence of a threshold level of mitochondrial GSH that is required for protection. Determination of this threshold concentration will require a more systematic analysis of correlations between transport rates, mitochondrial GSH content, and cellular susceptibility. The reported association of depletion or oxidation of hepatic mitochondrial GSH with several disease states, including chronic alcohol consumption and alcoholic liver disease (Fernandez-Checa et al., 1993Go) and cirrhosis and other forms of biliary obstruction (Krahenbuhl et al., 1992Go, 1995Go), emphasizes the importance of understanding how mitochondrial GSH is regulated. In the kidneys, studies have not directly addressed the question of mitochondrial GSH and disease, although diabetic nephropathy is associated with oxidative stress and GSH oxidation (Obrosova et al., 2003Go). The potential clinical significance of modulating mitochondrial GSH content is further highlighted by a study using mouse B16 melanoma cells, in which the authors proposed that maintenance of mitochondrial GSH homeostasis may be required for survival of metastatic cells (Ortega et al., 2003Go). Hence, additional understanding of the regulation of mitochondrial GSH status and modulation of GSH levels holds promise for development of novel therapeutic approaches for many diseases and chemically induced toxicities.


    Footnotes
 
This work was funded by National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Grant R01-DK40725 (to L.H.L. and L.H.M.). Core facilities funded by the National Institute of Environmental Health Sciences, National Institutes of Health Center for Molecular Toxicology with Human Applications (Grant P30-ES06639) at Wayne State University were used for some of these experiments.

doi:10.1124/jpet.105.094599.

ABBREVIATIONS: GSH, glutathione; DIC, dicarboxylate carrier; 2-OG, 2-oxoglutarate; OGC, oxoglutarate carrier; rDIC, rat dicarboxylate carrier; tBH, tert-butyl hydroperoxide; WT, wild-type; rOGC, rat 2-oxoglutarate carrier; DCVC, S-(1,2-dichlorovinyl)-L-cysteine; PCR, polymerase chain reaction; SDS, sodium dodecyl sulfate; RT-PCR, reverse transcription-polymerase chain reaction; bp, base pair(s); Mes, 4-morpholineethanesulfonic acid; TMD, transmembrane domain; PLP, pyridoxal 5'-phosphate; PhSucc, phenylsuccinate.

Address correspondence to: Dr. Lawrence H. Lash, Department of Pharmacology, Wayne State University School of Medicine, 540 East Canfield Ave., Detroit, MI 48201. E-mail: l.h.lash{at}wayne.edu


    References
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

Beatrice MC, Stiers DL, and Pfeiffer DR (1984) The role of glutathione in the retention of Ca2+ by liver mitochondria. J Biol Chem 259: 1279–1287.[Abstract/Free Full Text]

Bisaccia F, Indiveri C, and Palmieri F (1985) Purification of reconstitutively active {alpha}-oxoglutarate carrier from pig heart mitochondria. Biochim Biophys Acta 810: 362–369.[Medline]

Bisaccia F, Indiveri C, and Palmieri F (1988) Purification and reconstitution of two anion carriers from rat liver mitochondria: the dicarboxylate and 2-oxoglutarate carrier. Biochim Biophys Acta 933: 229–240.[Medline]

Chen Z and Lash LH (1998) Evidence for mitochondrial uptake of glutathione by dicarboxylate and 2-oxoglutarate carriers. J Pharmacol Exp Ther 285: 608–618.[Abstract/Free Full Text]

Chen Z, Putt DA, and Lash LH (2000) Enrichment and functional reconstitution of glutathione transport activity from rabbit kidney mitochondria: further evidence for the role of the dicarboxylate and 2-oxoglutarate carriers in mitochondrial glutathione transport. Arch Biochem Biophys 373: 193–202.[CrossRef][Medline]

Coll O, Colell A, Garcia-Ruiz C, Kaplowitz N, and Fernandez-Checa JC (2003) Sensitivity of the 2-oxoglutarate carrier to alcohol intake contributes to mitochondrial glutathione depletion. Hepatology 38: 692–702.[Medline]

Cooper AJL, Bruschi SA, and Anders MW (2002) Toxic, halogenated cysteine S-conjugates and targeting of mitochondrial enzymes of energy metabolism. Biochem Pharmacol 64: 553–564.[CrossRef][Medline]

Dolce V, Messina A, Cambria A, and Palmieri F (1994) Cloning and sequencing of the rat cDNA encoding the mitochondrial 2-oxoglutarate carrier protein. DNA Seq 5: 103–109.[Medline]

Elfarra AA, Jakobson I, and Anders MW (1986) Mechanism of S-(1,2-dichlorovinyl)-glutathione-induced nephrotoxicity. Biochem Pharmacol 35: 283–288.[CrossRef][Medline]

Fernandez-Checa JC, Hirano T, Tsukamoto H, and Kaplowitz N (1993) Mitochondrial glutathione depletion in alcoholic liver disease. Alcohol 10: 469–475.[CrossRef][Medline]

Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, Colell A, Miranda M, Mari M, Ardite E, and Morales E (1997) GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol 273: G7–G17.[Medline]

Fiermonte G, Dolce V, Palmieri L, Ventura M, Runswick MJ, Palmieri F, and Walker JE (2001) Identification of the human mitochondrial oxodicarboxylate carrier: bacterial expression, reconstitution, functional characterization, tissue distribution and chromosomal location. J Biol Chem 276: 8225–8230.[Abstract/Free Full Text]

Fiermonte G, Palmieri L, Dolce V, Lasorsa FM, Palmieri F, Runswick MJ, and Walker JE (1998) The sequence, bacterial expression and functional reconstitution of the rat mitochondrial dicarboxylate transporter cloned via distant homologs in yeast and Caenorhabditis elegans. J Biol Chem 273: 24754–24759.[Abstract/Free Full Text]

Griffith OW and Meister A (1985) Origin and turnover of mitochondrial glutathione. Proc Natl Acad Sci USA 82: 4668–4672.[Abstract/Free Full Text]

Halestrap AP (1975) The mitochondrial pyruvate carrier: kinetics and specificity for substrates and inhibitors. Biochem J 148: 85–96.[Medline]

Hayden PJ and Stevens JL (1990) Cysteine conjugate toxicity, metabolism and binding to macromolecules in isolated rat kidney mitochondria. Mol Pharmacol 37: 468–476.[Abstract]

Kakhniashvili D, Mayor JA, Gremse DA, Xu Y, and Kaplan RS (1997) Identification of a novel gene encoding the yeast mitochondrial dicarboxylate transport protein via overexpression, purification and characterization of its protein product. J Biol Chem 272: 4516–4521.[Abstract/Free Full Text]

Kaplan RS and Pedersen PL (1985) Isolation and reconstitution of the n-butylmalonate-sensitive dicarboxylate transporter from rat liver mitochondria. J Biol Chem 260: 10293–10298.[Abstract/Free Full Text]

Krahenbuhl S, Stucki J, and Reichen J (1992) Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. Hepatology 15: 1160–1166.[Medline]

Krahenbuhl S, Talos C, Lauterburg BH, and Reichen J (1995) Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats. Hepatology 22: 607–612.[CrossRef][Medline]

Kroemer G, Dallaporta B, and Resche-Rigon M (1998) The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 60: 619–642.[CrossRef][Medline]

Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227: 680–685.[CrossRef][Medline]

Lançar-Benba J, Foucher B, and Saint-Macary M (1994) Purification of the rat-liver mitochondrial dicarboxylate carrier by affinity chromatography on immobilized malate dehydrogenase. Biochim Biophys Acta 1190: 213–216.[Medline]

Lash LH and Anders MW (1987) Mechanism of S-(1,2-dichlorovinyl)-L-cysteine- and S-(1,2-dichlorovinyl)-L-homocysteine-induced renal mitochondrial toxicity. Mol Pharmacol 32: 549–556.[Abstract]

Lash LH, Hueni SE, and Putt DA (2001) Apoptosis, necrosis and cell proliferation induced by S-(1,2-dichlorovinyl)-L-cysteine in primary cultures of human proximal tubular cells. Toxicol Appl Pharmacol 177: 1–16.[CrossRef][Medline]

Lash LH, Putt DA, Hueni SE, Cao W, Xu F, Kulidjian SJ, and Horwitz JP (2002a) Cellular energetics and glutathione status in NRK-52E cells: toxicological implications. Biochem Pharmacol 64: 1533–1546.[CrossRef][Medline]

Lash LH, Putt DA, and Matherly LH (2002b) Protection of NRK-52E cells, a rat renal proximal tubular cell line, from chemical-induced apoptosis by overexpression of a mitochondrial glutathione transporter. J Pharmacol Exp Ther 303: 476–486.[Abstract/Free Full Text]

Lash LH, Visarius TM, Sall JM, Qian W, and Tokarz JJ (1998) Cellular and subcellular heterogeneity of glutathione metabolism and transport in rat kidney cells. Toxicology 130: 1–15.[CrossRef][Medline]

Lê-Quôc K and Lê-Quôc D (1985) Crucial role of sulfhydryl groups in the mitochondrial inner membrane structure. J Biol Chem 260: 7422–7428.[Abstract/Free Full Text]

Martensson J and Meister A (1989) Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester. Proc Natl Acad Sci USA 86: 471–475.[Abstract/Free Full Text]

McKernan TM, Woods EB, and Lash LH (1991) Uptake of glutathione by renal cortical mitochondria. Arch Biochem Biophys 288: 653–663.[CrossRef][Medline]

Obrosova IG, Fathallah L, Liu E, and Nourooz-Zadeh J (2003) Early oxidative stress in the diabetic kidney: effect of DL-{alpha}-lipoic acid. Free Radic Biol Med 34: 186–195.[CrossRef][Medline]

Ortega AL, Carretero J, Obrador E, Gambini J, Asensi M, Rodilla V, and Estrela JM (2003) Tumor cytotoxicity by endothelial cells: impairment of the mitochondrial system for glutathione uptake in mouse B16 melanoma cells that survive after in vivo interaction with the hepatic sinusoidal endothelium. J Biol Chem 278: 13888–13897.[Abstract/Free Full Text]

Palmieri F, Bisaccia F, Capobianco L, Dolce V, Fiermonte G, Iacobazzi V, Indiveri C, and Palmieri L (1996) Mitochondrial metabolite transporters. Biochim Biophys Acta 1275: 127–132.[Medline]

Reed DJ (1990) Glutathione: toxicological implications. Annu Rev Pharmacol Toxicol 30: 603–631.[Medline]

Schnellmann RG (1991) Renal mitochondrial glutathione transport. Life Sci 49: 393–398.[CrossRef][Medline]

Schnellmann RG, Gilchrist SM, and Mandel LJ (1988) Intracellular distribution and depletion of glutathione in rabbit renal proximal tubules. Kidney Int 34: 229–233.[Medline]

Shan X, Jones DP, Hashmi M, and Anders MW (1993) Selective depletion of mitochondrial glutathione concentrations by (R,S)-3-hydroxy-4-pentenoate potentiates oxidative cell death. Chem Res Toxicol 6: 75–81.[CrossRef][Medline]

Smith CV, Jones DP, Guenther TM, Lash LH, and Lauterburg BH (1996) Compartmentation of glutathione: implications for the study of toxicity and disease. Toxicol Appl Pharmacol 140: 1–12.[CrossRef][Medline]

van de Water B, Zoeteweij JP, de Bont HJGM, and Nagelkerke JF (1995) Inhibition of succinate:ubiquinone reductase and decrease of ubiquinol in nephrotoxic cysteine S-conjugate-induced oxidative cell injury. Mol Pharmacol 48: 928–937.[Abstract]

Yagi T and Hatefi Y (1984) Thiols in oxidative phosphorylation: inhibition and energy-potentiated uncoupling by monothiol and dithiol modifiers. Biochemistry 23: 2449–2455.[CrossRef][Medline]


This article has been cited by other articles:


Home page
IOVSHome page
L. Wang, Y. Chen, P. Sternberg, and J. Cai
Essential Roles of the PI3 Kinase/Akt Pathway in Regulating Nrf2-Dependent Antioxidant Functions in the RPE
Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1671 - 1678.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
G. Kroemer, L. Galluzzi, and C. Brenner
Mitochondrial Membrane Permeabilization in Cell Death
Physiol Rev, January 1, 2007; 87(1): 99 - 163.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.094599v1
316/3/1175    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, F.
Right arrow Articles by Lash, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, F.
Right arrow Articles by Lash, L. H.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition